When a company cans its CEO, gets its shares delisted and says its past financial statements may be fictions — well, perhaps it’s time to buy.
That’s one takeaway from a report issued Tuesday by Eiad Asbahi, founder of activist short seller Prescience Point Capital Management, who is recommending buying shares of one of the most loathed stocks of 2017: MiMedx Group.
The
